|1.||Hawthorne, Thomas: 4 articles (01/2016 - 10/2014)|
|2.||Simantov, Ronit: 4 articles (11/2014 - 04/2010)|
|3.||Crowley, Elizabeth: 3 articles (05/2015 - 11/2014)|
|4.||Siegel, Peter M: 3 articles (11/2014 - 04/2010)|
|5.||Kolb, E Anders: 2 articles (01/2016 - 10/2014)|
|6.||Gorlick, Richard: 2 articles (01/2016 - 10/2014)|
|7.||Green, Jennifer: 2 articles (05/2015 - 11/2014)|
|8.||Vahdat, Linda T: 2 articles (05/2015 - 02/2012)|
|9.||Davis, Thomas A: 2 articles (05/2015 - 11/2014)|
|10.||Forero, Andres: 2 articles (05/2015 - 06/2014)|
|1.||Breast Neoplasms (Breast Cancer)
05/10/2015 - "This phase II study investigated the activity of glembatumumab vedotin in advanced breast cancer by gpNMB expression. "
11/10/2014 - "This is, to our knowledge, the first study of glembatumumab vedotin in breast cancer. "
11/10/2014 - "Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with locally advanced or metastatic breast cancer."
05/10/2015 - "Glembatumumab vedotin is well tolerated in heavily pretreated patients with breast cancer. "
06/01/2014 - "Although in unselected patients with metastatic breast cancer glembatumumab vedotin was not superior to other agents, by virtue of its target being frequently and highly expressed in triple-negative breast cancer, its activity was particularly promising in this subset of patients. "
|2.||Melanoma (Melanoma, Malignant)
11/10/2014 - "This study evaluated the safety and activity of glembatumumab vedotin in patients with advanced melanoma. "
11/10/2014 - "Phase I/II study of the antibody-drug conjugate glembatumumab vedotin in patients with advanced melanoma."
06/01/2010 - "Ongoing phase II trials suggest that CDX-011 has activity against advanced cutaneous melanomas. "
11/10/2014 - "Glembatumumab vedotin is generally well tolerated, with observed objective responses in advanced melanoma. "
11/10/2014 - "Glembatumumab vedotin is active in advanced melanoma. "
05/10/2015 - "Patients (n = 124) with refractory breast cancer that expressed gpNMB in ≥ 5% of epithelial or stromal cells by central immunohistochemistry were stratified by gpNMB expression (tumor, low stromal intensity, high stromal intensity) and were randomly assigned 2:1 to glembatumumab vedotin (n = 83) or investigator's choice (IC) chemotherapy (n = 41). "
04/01/2010 - "In human melanoma xenograft mice, intravenous glembatumumab vedotin was associated with complete tumor regression without significant toxicity. "
10/01/2014 - "Glembatumumab vedotin was administered intravenously at a dose of 2.5 mg/kg using a weekly × 3 schedule, and its antitumor activity was evaluated against selected Pediatric Preclinical Testing Program (PPTP) solid tumor xenografts using standard PPTP response metrics. "
04/01/2010 - "CDX-011 (glembatumumab vedotin) is a promising new targeted therapy for patients with metastatic triple-negative breast cancers, a patient population that currently lacks targeted-therapy options."
04/01/2010 - "Glembatumumab vedotin (CR-011-vc-MMAE) is a mAb-drug conjugate being developed by Celldex Therapeutics Inc for the treatment of glycoprotein non-metastatic melanoma protein B (GPNMB)-expressing cancers. "
|4.||Osteosarcoma (Osteogenic Sarcoma)
01/01/2016 - "GPNMB is expressed in osteosarcoma and targeting GPNMB with the antibody-drug conjugate glembatumumab vedotin demonstrates osteosarcoma cytotoxic activity. "
10/01/2014 - "Glembatumumab vedotin induced statistically significant differences (P < 0.05) in event-free survival (EFS) distribution compared to control in each of the six osteosarcoma models studied. "
10/01/2014 - "Glembatumumab vedotin yielded high-level activity against three of six osteosarcoma xenografts, with evidence for response being related to GPNMB expression levels."
01/01/2016 - "Targeting Glycoprotein NMB With Antibody-Drug Conjugate, Glembatumumab Vedotin, for the Treatment of Osteosarcoma."
|4.||monomethyl auristatin E
|7.||IgA receptor (protein B)
|8.||N- propyl- 4- phenyl- 1,2,3,6- tetrahydropyridine (PPTP)
|1.||Heterologous Transplantation (Xenotransplantation)
|3.||Drug Therapy (Chemotherapy)